Drug Profile

Research programme: Huntington's disease gene therapy - NeuExcell Therapeutics

Alternative Names: NXL-002

Latest Information Update: 11 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuExcell Therapeutics
Class Gene therapies; Neuroprotectants
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Huntington's disease

Most Recent Events

11 Jan 2023 Early research in Huntington's disease in USA (Parenteral) Before January 2023 (NeuExcell Therapeutics pipeline, January 2023)
13 Oct 2022 NeuExcell Therapeutics plans to file an IND application for Huntington's disease program in Q2 2024 (NeuExcell Therapeutics pipeline, January 2023)
13 Mar 2020 Preclinical trials in Huntington's disease in USA (Parenteral) prior to March 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com